Guardian Pharmacy Services Projects Low Double-Digit EBITDA Growth for 2026 Despite IRA Impact
GRDN sits 76% above its 52-week low of $17.78.
Summary
Guardian Pharmacy Services reiterated its 2025 financial guidance and provided a positive preliminary outlook for 2026, projecting low double-digit adjusted EBITDA growth despite the impact of the Inflation Reduction Act.
Key Events · Earnings and Guidance · GRDN
-
2026 Financial Outlook
The company projects 2026 adjusted EBITDA in the range of $115 million to $118 million, representing approximately 11% year-over-year growth from 2025 guidance.
-
Margin Improvement
Adjusted EBITDA margin is expected to structurally improve to above 8% in 2026, a step-up from 2025.
-
Inflation Reduction Act Impact
2026 revenue is projected to be $1.40 billion to $1.42 billion, reflecting the effects of drug pricing reforms under the Inflation Reduction Act and WAC reductions. Excluding these impacts, revenue growth would be in the high single digits.
-
2025 Guidance Reiteration
Guardian Pharmacy Services reiterated its previously announced 2025 revenue guidance of $1.43 billion to $1.45 billion and adjusted EBITDA guidance of $104 million to $106 million.
Analysis · GRDN · Trade & Services
Guardian Pharmacy Services provided its preliminary financial outlook for 2026, projecting low double-digit adjusted EBITDA growth and an improved margin profile, even with anticipated revenue reductions from the Inflation Reduction Act. This demonstrates the company's resilience and strategic planning in navigating regulatory changes. The reiteration of 2025 guidance and a modest strategic acquisition further support a stable operational outlook.
At the time of this filing, GRDN was trading at $31.26 on NYSE in the Trade & Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $17.78 to $37.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.